Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Silberman

Showing results (81-90 of 87) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 87 results.
The Journal of Thoracic and Cardiovascular Surgery|April 1, 1984
The broadly based pericardial flap. A tissue for atrial wall replacement that growsR A Guyton, L M Dorsey, M S Silberman, et al.
Journal of Neuro-Oncology|February 1, 1993
Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHAE W Jeffes, Y B Beamer, S Jacques, et al.
The New England Journal of Medicine|April 5, 2001
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorH Joensuu, P J Roberts, M Sarlomo-Rikala, et al.
Lancet (London, England)|November 14, 2001
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyA T van Oosterom, I Judson, J Verweij, et al.
Genome Biology|December 25, 2012
A microRNA network regulates proliferative timing and extracellular matrix synthesis during cellular quiescence in fibroblastsEric J Suh, Matthew Y Remillard, Aster Legesse-Miller, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)S Stroobants, J Goeminne, M Seegers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesM Hidalgo, L L Siu, J Nemunaitis, et al.
Pageof 9

Showing results (81-90 of 87) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 87 results.
The Journal of Thoracic and Cardiovascular Surgery|April 1, 1984
The broadly based pericardial flap. A tissue for atrial wall replacement that growsR A Guyton, L M Dorsey, M S Silberman, et al.
Journal of Neuro-Oncology|February 1, 1993
Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHAE W Jeffes, Y B Beamer, S Jacques, et al.
The New England Journal of Medicine|April 5, 2001
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorH Joensuu, P J Roberts, M Sarlomo-Rikala, et al.
Lancet (London, England)|November 14, 2001
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyA T van Oosterom, I Judson, J Verweij, et al.
Genome Biology|December 25, 2012
A microRNA network regulates proliferative timing and extracellular matrix synthesis during cellular quiescence in fibroblastsEric J Suh, Matthew Y Remillard, Aster Legesse-Miller, et al.
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)S Stroobants, J Goeminne, M Seegers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2001
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignanciesM Hidalgo, L L Siu, J Nemunaitis, et al.
Pageof 9